Given the emerging importance of the roles of MUC1 TRD-STs in the complex immune systems through the interaction with members of the Siglec family,7,11,29,30 our interest was centred on the structural basis in the interaction of SN-131 with MUC1 TRD-ST(s) and the potentials of SN-131 as a new class of anticancer therapeutic reagents targeting the pancreatic cancer cells. The gene discussed is MUC1; the disease is familial pancreatic carcinoma.